← Eichor
Study identifier: NCT06448013 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 1
Planned participants22
Who can joinAll sexes, 3 Years to 21 Years
Healthy volunteersNo

About this study

To find the recommended dose of ziftomenib in combination with gemtuzumab ozogamicin and venetoclax that can be given to pediatric participants who have relapsed or refractory AML or MPAL.

This description comes directly from the study's public registry record.

Talk to the study team

Branko Cuglievan, MD  ·  (713) 563-1499  ·  bcuglievan@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (1)

MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06448013